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Abstract
Rationale: In the context of rapid antiretroviral therapy rollout
and an increasing burden of noncommunicable diseases, there are
few contemporary data describing the etiology and outcome of
community-acquired pneumonia (CAP) in sub-Saharan Africa.
Objectives: To describe the current etiology of CAP in Malawi and
identify risk factors for mortality.
Methods:We conducted a prospective observational study of adults
hospitalized with CAP to a teaching hospital in Blantyre, Malawi.
Etiology was deﬁned by blood culture, Streptococcus pneumoniae
urinary antigen detection, sputum mycobacterial culture and Xpert
MTB/RIF, and nasopharyngeal aspirate multiplex PCR.
Measurements and Main Results: In 459 patients (285 [62.1%]
males; median age, 34.7 [interquartile range, 29.4–41.9] yr), 30-day
mortality was 14.6% (64/439) and associated with male sex (adjusted
odds ratio, 2.60 [95% conﬁdence interval, 1.17–5.78]), symptom
duration greater than 7 days (2.78 [1.40–5.54]), tachycardia
(2.99 [1.48–6.06]), hypoxemia (4.40 [2.03–9.51]), and inability to
stand (3.59 [1.72–7.50]). HIV was common (355/453; 78.4%),
frequently newly diagnosed (124/355; 34.9%), but not associatedwith
mortality. S. pneumoniae (98/458; 21.4%) and Mycobacterium
tuberculosis (75/326; 23.0%) were the most frequently identiﬁed
pathogens. Viral infection occurred in 32.6% (148/454) with
inﬂuenza (40/454; 8.8%) most common. Bacterial–viral coinfection
occurred in 9.1% (28/307). Detection ofM. tuberculosis was
associated with mortality (adjusted odds ratio, 2.44 [1.19–5.01]).
Conclusions: In the antiretroviral therapy era, CAP in Malawi
remains predominantly HIV associated, with a large proportion
attributable to potentially vaccine-preventable pathogens.
Strategies to increase early detection and treatment of tuberculosis
and improve supportive care, in particular the correction of
hypoxemia, should be evaluated in clinical trials to address CAP-
associated mortality.
Keywords: community-acquired pneumonia; HIV; Africa south of
the Sahara; Streptococcus pneumoniae; pulmonary tuberculosis
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Globally, pneumonia is the commonest
infectious cause of death and the second
leading cause of overall life years lost (1). In
sub-Saharan Africa alone, lower respiratory
tract infections account for 390,000 deaths
in older children and adults each year (2).
Although the etiology and outcome of
community-acquired pneumonia (CAP)
has been thoroughly investigated in large
cohorts of adults in well-resourced settings
in Europe and North America (3, 4) and
more recently in young children (,5 yr)
from sub-Saharan Africa (5), contemporary
data on acute CAP in adults from sub-
Saharan Africa are limited. With the
exception of cohorts from South Africa
(6, 7), recent studies are small (8, 9),
retrospective (10), or only use a restricted
panel of investigations to deﬁne etiology (11).
In Malawi, a very-low-income country
in Southern Africa, pneumonia is the
commonest cause of adult hospitalization
(12). There is a generalized HIV epidemic
(adult prevalence 10.6%) (13) and high
tuberculosis (TB) incidence (159 cases per
100,000 population) (14). These factors
create a backdrop distinct from most well-
resourced settings and common to many
countries in the region that is likely to have
a substantial bearing on the epidemiology
and etiology of CAP; more comprehensive
data are therefore crucial to develop
appropriate context-speciﬁc management
guidelines (15). Given the continued rollout
of antiretroviral therapy (ART) (16), recent
introduction of infant pneumococcal
conjugate vaccination (17), and the
broader context of rapidly increasing life
expectancy and emergence of chronic
noncommunicable diseases (18),
contemporaneous data are vital. We
therefore conducted a prospective study of
adults hospitalized with CAP to the largest
central hospital in Malawi to describe
etiology and to identify risk factors for
mortality to inform the development of
local guidelines for antibiotic choice and
severity assessment. Some of the results of
this study have been previously reported in
the form of abstracts (19, 20).
Methods
Study Setting and Design
We conducted a prospective observational
study of adults hospitalized with CAP at
Queen Elizabeth Central Hospital, a 1,200-
bed teaching hospital that provides free
healthcare to the 1.3 million residents of
Blantyre district in SouthernMalawi. Ethical
approval was provided by the Research
Ethics Committees of University of Malawi
College of Medicine (P.11/12/1309) and
Liverpool School of Tropical Medicine
(13.02). Some patients participated in linked
case-control studies describing the impact of
HIV on inﬂuenza severity (21) and the
association of indoor air pollution exposure
with pneumonia (22).
Study Procedures
We recruited adults (>18 yr) hospitalized
with clinically diagnosed CAP deﬁned as:
reported or recorded fever (>388C), at least
one relevant symptom (cough, chest pain,
breathlessness, hemoptysis), and at least
one focal chest sign (crepitations, pleural
rub, bronchial breathing, percussive
dullness, or diminished breath sounds)
(adapted from Reference 23). Patients with
symptoms for more than 14 days, current
antituberculous treatment, or prior
admission within the last month were
excluded. Further details of the eligibility
criteria are provided in the online
supplement. Written informed consent was
provided by the patient, or in the case
of incapacity, by their accompanying
guardian.
Patients underwent a standardized
clinical assessment on admission and were
reviewed daily during hospitalization and
then followed at 30 and 90 days after
admission to determine vital status. Blood,
urine, sputum, and nasopharyngeal aspirate
(NPA) were collected at enrolment.
Diagnostic pleural aspiration was performed
in patients with radiologically conﬁrmed
pleural effusion. Clinical care was provided
in accordance with local guidelines and
directed by the patients’ clinical team.
Radiographic Assessment
Chest radiographs were performed
as early as possible after admission
and independently reported by two
radiologists and a study clinician using a
standardized form. A consensus report of
the three assessors was used for analysis.
Radiographic pneumonia was deﬁned
as the presence of consolidation or other
parenchymal abnormality (including
reticulonodular change, cavitation, or
miliary appearance) or pleural effusion (4).
Additional details are provided in the
online supplement.
Laboratory Testing
Hematologic and biochemical analyses were
performed by standard methods. HIV status
was established by sequential rapid tests
(Determine, Alere; and Uni-Gold, Trinity
Biotech) (24) and CD4 cell count was
performed on FACSCount ﬂow cytometer
(Becton Dickinson). Blood cultures were
performed using aerobic bottles in the
BacT/ALERT 3D automated system
(bioMe´rieux) and isolates identiﬁed using
standard procedures (25). Urine antigen
testing was performed for the detection of
Streptococcus pneumoniae (BinaxNOW,
Alere) and, in a subset of patients,
Legionella pneumophila (BinaxNOW,
Alere). A PCR assay was performed on NPA
specimens for the detection of adenovirus;
bocavirus; Chlamydophila pneumoniae;
At a Glance Commentary
Scientiﬁc Knowledge on the
Subject: In the antiretroviral therapy
era, community-acquired pneumonia
(CAP) remains the commonest cause
of adult hospitalization and a major
cause of mortality in many sub-
Saharan Africa HIV-affected countries.
With the exception of cohorts from
South Africa, contemporary studies
describing CAP etiology and outcome
from the region are either small,
retrospective, or only use limited
investigations to deﬁne etiology.
Current CAP management protocols
applied in sub-Saharan Africa are
therefore inadequately informed by
contemporary data.
What This Study Adds to the
Field: In a large prospective cohort of
hospitalized adults in Malawi we show
that the major burden of hospitalized
acute CAP remains in young, HIV-
infected patients and that Streptococcus
pneumoniae, tuberculosis, and
inﬂuenza predominate as the major
causes. CAP mortality is high
compared with populations from
well-resourced settings with similar
age proﬁles and is associated with
potentially modiﬁable risk factors
including hypoxemia. Death from
CAP is poorly predicted by commonly
used CAP severity-assessment tools,
such as CURB65.
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coronaviruses 229E, HKU1, OC43,
and NL63; enterovirus; human
metapneumovirus; inﬂuenza A and B
viruses; Mycoplasma pneumoniae;
parainﬂuenza virus types 1–4; parechovirus;
respiratory syncytial viruses, and rhinovirus.
Xpert MTB/RIF assay (Cepheid) and
mycobacterial microscopy and culture
(BACTEC MGIT 960 Mycobacterial
Detection System, Becton Dickinson) were
performed on noninduced sputum
specimens. When obtained, pleural ﬂuid
samples were sent for Gram stain, aerobic
culture, mycobacterial microscopy and
culture, and pneumococcal antigen testing.
Further details of laboratory methods are
provided in the online supplement.
Statistical Analysis
Statistical analyses were performed with
Stata version 12.1 (StataCorp). We tested for
differences in continuous variables using
Wilcoxon rank sum test, and categorical
variables by chi-square test or Fisher exact
test as appropriate. Differences in microbial
etiology by radiographic status controlling
for the effect of HIV were examined using
the Mantel-Haenszel method.
Candidate risk factors for 30-day
mortality were selected a priori based on
literature review (26–29). Continuous
variables, with the exception of age, were
dichotomized at standard cutoff points
(29–32). Univariable analyses were
performed using logistic regression to
explore associations with 30-day mortality.
Multivariable models were generated using
age, sex, HIV status, and all variables with a
P value less than 0.2 on univariable analysis,
prevalence of at least 5% and for which data
were available in more than 95% of
patients, and then rationalized by stepwise
backward elimination with removal of
variables with a P value greater than
0.05. The number of covariates in the
multivariable model were limited to
maintain at least 10 events per variable
(33). Subgroup analyses of HIV-infected
patients and those with radiographic
pneumonia were performed. The
association of etiology with mortality was
also assessed (see online supplement). All
available case information was used in each
univariable analysis. In multivariable
models, we excluded patients with missing
data for included variables.
The prognostic performance of several
CAP severity-assessment tools, such as
CURB65 (29), CRB65 (29), SMRT-CO
(simpliﬁed version of the SMART-COP tool)
(34), modiﬁed Infectious Disease Society of
America/American Thoracic Society 2007
minor criteria (35), and SWAT-Bp (28), for
predicting 30-day mortality was described by
calculating sensitivity, speciﬁcity, positive
and negative predictive values, positive and
negative likelihood ratios, and area under the
receiver-operating characteristic curve with
95% conﬁdence intervals (CI). Details of how
scores were calculated for each severity-
assessment tool are provided in the online
supplement.
Results
Baseline Characteristics
Between May 15, 2013, and January 31,
2015, we screened 1,711 adult patients, of
whom 489 fulﬁlled the eligibility criteria,
472 were enrolled, and 459 included in the
analysis (Figure 1). The median age was
34.7 years (interquartile range, 29.4–41.9)
and 285 (62.1%) were male (Table 1; see
Table E1 in the online supplement). HIV
infection was common (355/453; 78.4%;
HIV status missing in six individuals) and
often newly diagnosed (124/355; 34.9%),
whereas other comorbid illnesses were
reported infrequently (31/451; 6.9%). A
total of 83.3% (189/227) of those known to
be HIV-infected reported current ART use.
Prior pneumonia was common (108/457;
23.6%) and associated with HIV (odds
ratio [OR], 2.91; 95% CI, 1.46–6.30). The
median length of admission was 7 days
(interquartile range, 4–10).
Radiographic pneumonia was
identiﬁed by consensus report in 317 (76.0%)
of 417 patients with available interpretable
chest radiographs with moderate
interobserver agreement (Kappa, 0.75; 95%
CI, 0.69–0.81) (Table 1; see Table E2).
Pleural effusion was identiﬁed in 118/416
(28.4%), being the sole basis of deﬁning
radiographic pneumonia in 38/315
(12.1%). The proportion of patients with
radiographic pneumonia did not vary with
HIV status (HIV-infected 247/320 [77.2%]
vs. HIV-uninfected 66/91 [72.5%]; P=0.36)
or with CD4 count (CD4, 200 cells/mm3
176/222 [79.3%] vs. CD4> 200 cells/mm3
49/64 [76.6%], P=0.64; CD4 count available
in 315/355 [88.7%] HIV-infected patients).
Etiology
Blood for aerobic culture was obtained from
450 of 459 (98.0%) of the participants, NPA
from 455/459 (99.1%), and urine
specimen for S. pneumoniae antigen
detection from 433/459 (94.3%) with
stored specimens available for Legionella
antigen testing in 193 (see Table E5).
At least one sputum specimen for a
mycobacterial diagnostic test was obtained
from 322/459 (70.2%) participants: smear
microscopy, mycobacterial culture, and
Xpert MTB/RIF assay were completed in
305/459 (66.4%), 273/459 (59.5%), and
308/459 (67.1%), respectively. A pleural
ﬂuid specimen was obtained in 35/459
(7.6%) patients: aerobic bacterial culture,
S. pneumoniae antigen detection, and
mycobacterial smear microscopy and
culture were completed in 31, 31, and 35
patients, respectively.
Overall at least one potential pathogen
was identiﬁed in 278/459 (60.6%) patients
including at least one bacterium in 125/452
(27.7%) and at least one virus in 148/459
(32.6%) (Table 2). S. pneumoniae was the
most commonly identiﬁed organism,
present in 98 (21.4%) of 458 for whom
results of blood culture and/or urinary
antigen assay were available, of whom 92
(93.9%) were identiﬁed by detection of
urinary antigen alone (see Table E5).
Pneumococcal etiology was more common
in HIV-uninfected patients (30/97 [30.9%]
vs. 68/355 [19.2%]; P= 0.01) and those with
radiographic pneumonia (83/316 [26.3%]
vs. 8/100 [8.0%]; P, 0.001) (see Table E6),
in particular conﬂuent consolidation (OR,
2.51; 95% CI, 1.26–4.98) (see Table E7).
Overall, 26 (5.8%) of 450 patients for whom
blood was sent for culture were bacteremic:
Salmonella enterica serovar Typhi (n= 9),
nontyphoidal Salmonella (n= 7), and
S. pneumoniae (n= 5) were most commonly
isolated. S. Typhi was identiﬁed more
frequently in HIV-uninfected patients
(5/94 [5%] vs. 3/350 [1%]; P= 0.02),
whereas all cases of nontyphoidal
Salmonella infection occurred in HIV-
infected patients, and both were more
common among patients lacking
radiographic pneumonia (see Table E6).
Infection with M. pneumoniae (6/455;
1.3%) and C. pneumoniae (2/455; 0.4%)
were uncommon. None of the 193 patients
tested had a positive Legionella urinary
antigen assay result.
Overall, M. tuberculosis was identiﬁed
in 75 (23.0%) of 326 patients who
submitted a sputum and/or pleural ﬂuid
specimen (Table 2). TB was conﬁrmed by
culture in 65/75 (86.7%) and diagnosed on
ORIGINAL ARTICLE
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the basis of Xpert MTB/RIF alone,
sputum microscopy alone, or pleural
ﬂuid microscopy alone in 8/75 (10.7%),
1/75 (1.3%), and 1/75 (1.3%) patients,
respectively (see Table E5). Nontuberculous
mycobacteria were isolated in 8/273 (2.9%)
for whom sputum for culture was obtained,
of whom one was smear positive. The
frequency of TB did not differ signiﬁcantly
between the groups with and without
radiographic pneumonia (58/232 [25%] vs.
13/68 [19.1%]) (see Table E6), although in
the latter, TB displaced S. pneumoniae as
the most commonly identiﬁed pathogen,
with all cases occurring in HIV-infected
patients.
Inﬂuenza (40/454; 8.8%), adenovirus
(35/455; 7.7%), and coronavirus (31/455;
6.8%) were the most commonly detected
viruses. Detection of these respiratory
viruses was not associated with HIV status
or the presence of radiographic pneumonia
(Table 2; see Table E6).
Coinfection relationships were
investigated in 307 patients (66.9% of
cohort) for whom results for blood culture,
pneumococcal urine antigen, sputum
mycobacterial culture and/or Xpert
MTB/RIF, and NPA PCR were available. At
least one organism was detected in 206/307
(67.1%) and coinfection with two or
more organisms was present in 67/307
(21.8%) (Figure 2); the combination of
bacterial–viral coinfection was most
frequent (28/307; 9.1%). S. pneumoniae was
codetected in one-ﬁfth of patients with
inﬂuenza (6/31; 19.4%). M. tuberculosis was
isolated in 9.6% (7/73) of those with S.
pneumoniae (see Table E8). Detection of
multiple organisms did not vary with HIV
status (54/243 [22.2%] vs. 12/62 [19.4%]).
Mortality
A total of 439/459 (95.6%) patients were
successfully followed to 30 days, of whom 64
(14.6%) had died, including 15 and 31
within the ﬁrst 3 and 7 days following
admission, respectively (Table 1). A total of
418 were followed to 90 days, of whom an
additional 23 had died. Male sex (adjusted
OR [aOR], 2.60; 95% CI, 1.17–5.78), pre-
presentation symptom duration greater
than 7 days (aOR, 2.78; 95% CI, 1.40–5.54),
heart rate greater than or equal to 125 per
minute (aOR, 2.99; 95% CI, 1.48–6.06),
oxygen saturations less than 90% (aOR,
4.40; 95% CI, 2.03–9.51), and inability to
stand (aOR, 3.59; 95% CI, 1.72–7.50) were
independently associated with 30-day
mortality (Table 3). Neither age nor any
underlying comorbid illness, including
HIV, or initial antimicrobial treatment was
found to be signiﬁcantly associated with 30-
day mortality. Detection of S. pneumoniae
was associated with reduced mortality
(aOR, 0.40; 95% CI, 0.17–0.91) (see Table
E9), whereas TB was associated with
increased mortality (aOR, 2.44; 95% CI,
1.19–5.01). Mortality did not vary with
detection of multiple organisms compared
with a single organism (5/65 [7.7%] vs.
13/135 [9.6%]; P= 0.80).
In a subgroup analysis of the 342 HIV-
infected patients followed to Day 30,
symptom duration greater than 7 days
(aOR, 3.56; 95% CI, 1.60–7.93), heart rate
greater than or equal to 125 per minute
(aOR, 3.06; 95% CI, 1.40–6.71), oxygen
saturations less than 90% (aOR, 2.97; 95%
CI, 1.28–6.88), inability to stand (aOR, 4.25;
95% CI, 1.84–9.79), and CD4 count less
than 50 cells/mm3 (aOR, 2.30; 95% CI,
1.07–4.92) were associated with mortality
in multivariable analysis (see Table E10).
CD4 count less than 200 cells/mm3 was not
associated with mortality (OR, 1.63; 95%
CI, 0.69–3.83). In the subgroup of 305
patients with radiographic pneumonia
followed to Day 30, symptom duration
greater than 7 days (aOR, 3.30; 95% CI,
1.37–7.96), heart rate greater than or equal
Assessed for
eligibility
n=1,711
Eligible
n=489
Enrolled
n=472
Ineligible*
n=1,222
Illness duration >14 days (n=593)
Lack of focal chest signs (n=394)
Absent fever (n=243)
Prior hospitalisation (n=67)
Current TB treatment (n=49)
Admitted >24 hours (n=34)
Inability to consent (n=32)
Coexistent meningitis (n=28)
Age <18 years (n=26)
Terminal illness (n=14)
Prior participation (n=13)
Lack of relevant symptoms (n=9)
Unclear (n=143)
Refused consent
n=17
Not interested (n=7)
Fear of participation (n=5)
No time (n=1)
Not stated/unknown (n=4)
Analyzed
n=459
Not analyzed
n=13
Not eligible (n=8)
Records missing (n=3)
Withdrew (n=2)
Discharge outcome
n=457
Day 30 outcome
n=439
Day 90 outcome
n=418
Lost to follow-up
n=2
Absconded (n=2)
Lost to follow-up
n=18
Lost to follow-up
n=21
Figure 1. Recruitment and follow-up of a cohort of Malawian adults hospitalized with community-
acquired pneumonia. *Some patients were excluded for multiple reasons; hence, the sum of the
individual reasons exceeds the total number excluded. TB= tuberculosis.
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to 125 per minute (aOR, 2.66; 95% CI,
1.08–6.57), and multilobar consolidation
(aOR, 2.75; 95% CI, 1.17–6.47) were
signiﬁcantly associated with mortality, with
a trend toward an association for inability
to stand (aOR, 2.63; 95% CI, 1.00–6.89) (see
Table E11). Thirty-day mortality was,
however, signiﬁcantly higher in the small
group of patients for whom a chest
radiograph was unavailable (17/36 [47.2%]
vs. 47/403 [11.7%]; P, 0.0001) (see
Table E3).
Prognostic Performance of Severity-
Assessment Tools
Of the CAP severity-assessment tools
examined, SMRT-CO had the highest
sensitivity (89.7%; 95% CI, 72.6–97.8),
negative predictive value (96.8%; CI,
91.0–99.3%), and overall discriminatory
capability (area under receiver-operating
characteristic curve, 0.66; 95% CI,
0.57–0.75) for 30-day mortality (Table 4).
CURB65 had poor sensitivity and
discriminatory capability. Only 38 (8.8%)
patients had “severe CAP” by CURB65
(i.e., score> 3) and mortality among those
with “mild CAP” (i.e., CURB65< 1)
was 10.8% (29/268). The prognostic
performance of each tool was similarly
poor in the subgroup with radiographic
pneumonia (see Table E12).
Discussion
In this prospective study of acute CAP in
adults that is among the largest conducted
in sub-Saharan Africa, we have shown
that: the burden of hospitalized pneumonia
in adults predominantly remains in
young, HIV-infected patients; TB and
vaccine-preventable pathogens, such as S.
pneumoniae and inﬂuenza, are common;
and mortality is substantial and associated
with potentially modiﬁable risk factors but
poorly predicted by widely used CAP
severity-assessment tools.
Although completed within the era of
ART scale-up, 35% of HIV-infected patients
were newly diagnosed, 17% of those with
known HIV were not receiving ART, and
more than three-quarters had advanced
immunosuppression (i.e., CD4, 200
cells/mm3). Further substantial reductions
in CAP incidence may therefore be
achieved by improved HIV testing and
linkage to early initiation of ART (36).
Table 1. Demographic, Clinical, and Radiographic Characteristics of 459 Malawian
Adults Hospitalized with Community-acquired Pneumonia
Characteristic n (%) of Episodes
Demographics
Male 285/459 (62.1)
Age* 34.7 (29.4–41.9)
HIV status
HIV positive† 355/453 (78.4)
Newly diagnosed 124/355 (34.9)
CD4 cell count, cells/mm3†
All HIV positive* 99 (44–193)
Newly diagnosed HIV positive* 93 (43–179)
ART use in known HIV positive† 189/227 (83.3)
Medical history
Any other comorbid condition 31/451 (6.9)
Chronic lung disease‡ 15/452 (3.3)
Chronic heart diseasex 3/452 (0.7)
Hypertension 8/452 (1.8)
Previous tuberculosisk 84/458 (18.3)
Previous pneumonia in last 5 yr¶ 108/457 (23.6)
Pregnancy 2/174 (1.2)
Current smoker 50/457 (10.9)
Prehospital/clinic attendance and treatment
Attended another health facility** 283/458 (61.8)
Antibiotics within 2 wk†† 280/455 (61.5)
Antimalarials within 2 wk 79/457 (17.3)
Traditional remedies within 2 wk 40/456 (8.8)
Baseline observations
Temperature, 8C* 37.9 (37.1–38.9)
,358C or >408C 14/459 (3.1)
Systolic BP, mm Hg* 106 (93–121)
,90 mm Hg 86/454 (18.9)
Diastolic BP, mm Hg* 68 (59–78)
<60 mm Hg 143/454 (31.5)
Heart rate, beats/min* 118 (102–132)
>125 beats/min 176/458 (38.4)
Respiratory rate, breaths/min* 29 (26–34)
>30 breaths/min 213/446 (47.8)
Oxygen saturations, %* 95 (91–98)
,90 % 73/450 (16.2)
Body mass index, kg/m2* 19.9 (18.2–21.8)
,18.5 kg/m2 132/444 (29.7)
Baseline laboratory results
Hemoglobin, g/dl* 11 (9.0–12.8)
,8 g/dl 74/449 (16.5)
White blood cells, 3109 cells/L* 7.7 (5.0–11.4)
,43109 cells/L 67/448 (15.0)
>153109 cells/L 63/448 (14.1)
Urea, mmol/L* 4.8 (3.3–8.0)
.7 mmol/L 137/450 (30.4)
Creatinine, mmol/L* 76 (59–100)
.120 mmol/L 76/448 (17.0)
Radiologic features‡‡
Radiographic pneumonia 317/417 (76.0)
Consolidation 251/313 (80.2)
Multilobar involvement 73/247 (29.6)
Cavitation 20/317 (6.3)
Pleural effusion 118/315 (37.5)
Outcomexx
Inpatient mortality 51/457 (11.2)
Day 30 mortality 64/439 (14.6)
Day 90 mortality 87/418 (20.8)
Definition of abbreviations: ART=antiretroviral therapy; BP=blood pressure.
Data are n/N (%) unless otherwise indicated. Variation in denominator reflects missing data unless
further specified.
*Median and interquartile range are shown.
†HIV status missing in six patients; CD4 count missing in 40 of all with HIV; ART usage missing in four
with known HIV.
‡Chronic lung disease includes asthma, chronic obstructive pulmonary disease, and bronchiectasis.
xChronic heart disease includes congestive cardiac failure, cor pulmonale, and dilated
cardiomyopathy.
jjAny previous episode of treated tuberculosis regardless of site and confirmation.
¶Any prior episode within the last 5 years of a syndrome compatible with lower respiratory tract
infection reviewed in a healthcare facility and treated with antibiotics.
**Included attendance to other hospital, health center, private clinic, traditional healer, or pharmacy.
††Excluded cotrimoxazole prophylaxis in HIV-infected individuals.
‡‡Chest radiographs available in 421 patients; reports based on consensus grading of assessors and
denominator may vary when consensus not obtained.
xxStatus at hospital discharge, Day 30, and Day 90 missing in 2, 20, and 41, respectively.
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At ﬁrst glance, the overall crude
mortality rate of 14.6% is comparable with
that seen in well-resourced settings (26, 29,
37). However, a recent U.K. cohort
reported 30-day mortality of 1.5% in
patients younger than 50 (38), suggesting a
substantially higher age-adjusted mortality
rate in our cohort. The identiﬁed
associations of TB and uncorrected
hypoxemia with death, may explain some
of this apparent large discrepancy in
mortality rate. In keeping with other
studies of acute CAP (7, 27, 28), we did
not ﬁnd evidence that HIV overall
inﬂuenced outcome; increased mortality
was evident in only the most profoundly
immunocompromised with CD4 cell count
less than 50 cells/ml.
Given the observed strong association
of hypoxemia with mortality, expansion of
supplemental oxygen provision, which
across much of sub-Saharan Africa is
currently severely limited (39), represents
an obvious strategy to be evaluated to
improve CAP outcomes. Programmatic
interventions in children in low-resource
settings based on improved oxygen supply
using oxygen concentrators have been
associated with a 35% reduction in
mortality (40). The lack of association
between respiratory rate and mortality
underlines the importance of expanding the
availability of pulse oximetry in tandem.
Similarly, the association of pre-
presentation symptom duration with
mortality suggests that interventions to
Table 2. Etiology of Community-acquired Pneumonia in Malawian Adults Stratiﬁed by HIV Status
Organism All* (n= 459) HIV Positive (n= 355) HIV Negative (n= 98) P Value for Difference†
Streptococcus pneumoniae 98/458 (21.4) 68/355 (19.2) 30/97 (30.9) 0.01
Salmonella enterica serovar Typhi 10/450 (2.2) 4/350 (1.1) 5/94 (5.3) 0.02‡
Nontyphoidal Salmonellax 7/450 (1.6) 7/350 (2) 0/94 (0) 0.35‡
Other GNEBk 3/450 (0.7) 3/350 (0.9) 0/94 (0) 1.00‡
Staphylococcus aureus 2/450 (0.4) 1/350 (0.3) 1/94 (1.1) 0.38‡
Mycoplasma pneumoniae 6/455 (1.3) 6/355 (1.7) 0/98 (0) 0.35‡
Chlamydophila pneumoniae 2/455 (0.4) 0/355 (0) 2/98 (2.0) 0.05‡
Legionella pneumophila 0/193 (0) 0/154 (0) 0/38 (0) —
Mycobacterium tuberculosis 75/326 (23.0) 64/257 (24.9) 10/64 (15.6) 0.12
Nontuberculous mycobacteria 8/273 (2.9) 5/217 (2.3) 3/52 (5.8) 0.19‡
Inﬂuenza viruses 40/454 (8.8) 30/354 (8.5) 9/98 (9.2) 0.83
Adenovirus 35/455 (7.7) 30/355 (8.5) 5/98 (5.1) 0.39‡
Coronaviruses 31/455 (6.8) 28/355 (7.9) 3/98 (3.1) 0.11‡
Parainﬂuenza viruses 17/455 (3.7) 15/355 (4.2) 1/98 (1) 0.21‡
Rhinovirus 17/455 (3.7) 15/355 (4.2) 2/98 (2) 0.55‡
Bocavirus 13/455 (2.9) 13/355 (3.6) 0/98 (0) 0.08‡
Metapneumovirus 9/455 (2.0) 8/355 (2.3) 1/98 (1) 0.69‡
RSV 8/455 (1.8) 4/355 (1.1) 3/98 (3.1) 0.18‡
Enterovirus 5/455 (1.1) 5/355 (1.4) 0/98 (0) 0.59‡
Parechovirus 5/455 (1.1) 5/355 (1.4) 0/98 (0) 0.59‡
No pathogen detected 181/459 (39.4) 137/355 (38.6) 42/98 (42.9) 0.44
Definition of abbreviations: GNEB=gram-negative enteric bacilli; RSV= respiratory syncytial virus.
Data are n/N (%). Denominators indicate number of patients with at least one relevant test available. S. pneumoniae diagnosis based on combination of
blood and pleural fluid culture and antigen assay of urine and pleural fluid.M. tuberculosis based on combination of sputum microscopy, culture and Xpert
MTB/RIF, and pleural fluid culture. Other organisms based on single test. Column totals exceed number of patients because multiple organisms were
detected in some.
*Includes six patients with missing HIV status in whom the following organisms were identified: Salmonella Typhi, one;M. tuberculosis, one; influenza, one;
parainfluenza, one; RSV, one; no pathogen detected, two.
†Chi-square test unless otherwise stated.
‡Fisher exact test.
xSalmonella enterica serovar Enteritidis and Salmonella enterica serovar Typhimurium combined.
jjEscherichia coli and Enterobacter cloacae combined.
14%
16%
15%
33%
2% 6%
3%
9%
2%
Single bacterial pathogen
Single viral pathogen
Single mycobacterial pathogen
Viral–viral codetection
Bacterial–viral codetection
Bacterial–mycobacterial codetection
Mycobacterial–viral codetection
Bacterial–mycobacterial–viral codetection
No pathogen detected
Figure 2. Bacterial, viral, and mycobacterial infection in isolation and combination in Malawian adults
hospitalized with community-acquired pneumonia. Etiology defined by blood culture, Streptococcus
pneumoniae urinary antigen detection, sputum mycobacterial culture and Xpert MTB/RIF, and
nasopharyngeal aspirate respiratory pathogen multiplex PCR. Analysis restricted to 307 patients with
results available for all tests.
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improve patient education to alter health
care–seeking behavior or referral
mechanisms within community healthcare
centers should be considered. The
continued substantial mortality rate beyond
Day 30 also warrants further study to devise
targeted interventions to enhance care
following discharge from hospital.
The use of objective CAP severity-
assessment tools has been shown to improve
the recognition of patients with severe CAP
likely to require intensive care support (41)
and those with mild disease who can be
safely managed as outpatients (42). Current
South African CAP guidelines recommend
that CURB65 is used to inform site of care
and initial antimicrobial treatment (43).
However, we found that CURB65 showed
poor prognostic performance in predicting
30-day mortality in this cohort compared
with its performance in CAP cohorts from
well-resourced settings (44). This variation
likely reﬂects differences in microbial
etiology, demographics, and comorbidity
proﬁles between this cohort and the patient
populations in which CURB65 was derived
(29), and underlines the importance of
prospective validation of prognostic tools in
relevant settings (29, 44). The similarly
poor performance of the SWAT-Bp score
that was derived in a lower respiratory
tract infection cohort from Malawi (28),
however, highlights the challenges of
developing a simple and accurate locally
adapted tool. Rather than attempting to
derive a single tool capable of accurately
predicting mortality across the whole
spectrum of disease severity, a tool with
high negative predictive performance aimed
at identifying those patients with a low risk
of adverse outcome suitable for outpatient
management may be more feasible and
equally useful. In this respect, the SMRT-
CO tool performed well with a negative
predictive value of 96.8%, but the inclusion
Table 3. Association of Candidate Clinical and Laboratory Risk Factors with 30-Day Mortality in Malawian Adults Hospitalized with
Community-acquired Pneumonia
Characteristic
Day 30 Survivors
(n= 375)
Day 30 Mortality
(n= 64)
Univariable Analysis Multivariable Analysis
OR (95% CI) P Value aOR (95% CI)
P
Value
Male 224/375 (59.7) 52/64 (81.3) 2.92 (1.51–5.66) 0.001 2.60 (1.17–5.78) 0.02
Age, yr 34 (29–42) 36 (32–42) 1.00 (0.98–1.03) 0.73 1.00 (0.97–1.03) 0.93
Current smoker 41/373 (11.0) 7/64 (10.9) 0.99 (0.43–2.33) 0.99 — —
Regular alcohol use 92/373 (24.7) 23/63 (36.5) 1.76 (1.00–3.09) 0.05 — —
Unemployed 109/357 (30.5) 13/61 (21.3) 0.62 (0.32–1.18) 0.15 — —
HIV positive 288/370 (77.8) 54/64 (84.4) 1.53 (0.75–3.15) 0.24 1.26 (0.49–3.21) 0.63
Chronic lung disease 11/371 (3.0) 3/61 (4.9) 1.69 (0.46–6.23) 0.43 —* —
Chronic heart disease 2/370 (0.5) 1/61 (1.6) 3.07 (0.27–34.35) 0.36 —* —
Renal disease 0/371 (0) 1/61 (1.6) — — —* —
Pre-presentation symptoms.7 d 138/374 (36.9) 36/63 (57.1) 2.28 (1.33–3.92) 0.003 2.78 (1.40–5.54) 0.004
Travel time> 1 h 278/373 (74.5) 51/62 (82.3) 1.58 (0.79–3.16) 0.19 — —
Previous review 231/375 (61.6) 42/63 (66.7) 1.25 (0.71–2.19) 0.44 — —
Temperature ,358C or >408C 13/375 (3.5) 1/64 (1.6) 0.44 (0.06–3.44) 0.44 —* —
Systolic BP,90 mm Hg 66/371 (17.8) 17/63 (27.0) 1.71 (0.92–3.16) 0.09 — —
Diastolic BP< 60 mm Hg 112/371 (30.2) 28/63 (44.4) 1.85 (1.07–3.19) 0.03 —† —
Mean arterial BP,65 mm Hg 46/371 (12.4) 15/63 (23.8) 2.21 (1.14–4.26) 0.02 —† —
Heart rate> 125/min 135/374 (36.1) 37/64 (57.8) 2.43 (1.42–4.16) 0.001 2.99 (1.48–6.06) 0.002
Resp. rate>30/min 172/364 (47.3) 33/62 (53.2) 1.27 (0.74–2.18) 0.39 — —
Oxygen saturation, 90% 45/368 (12.2) 27/63 (42.9) 5.38 (2.99–9.70) ,0.0001 4.40 (2.03–9.51) ,0.001
BMI, 18.5 kg/m2 108/366 (29.5) 20/61 (32.8) 1.17 (0.65–2.08) 0.61 —‡ —
MUAC, 230 mm 103/371 (27.8) 14/63 (22.2) 0.74 (0.39–1.40) 0.36 — —
Confusion 2/374 (0.5) 3/64 (4.7) 9.15 (1.50–55.87) 0.02 —* —
Inability to stand 57/375 (15.2) 30/64 (46.9) 4.92 (2.79–8.67) ,0.0001 3.59 (1.72–7.50) 0.001
Hemoglobin, 8 g/dl 55/368 (15.0) 18/61 (29.5) 2.38 (1.28–4.43) 0.006 — —
White cell count, 43109/L 50/367 (13.6) 15/61 (24.6) 2.07 (1.07–3.98) 0.03 — —
Platelets,1003 109/L 58/368 (15.8) 14/61 (23.0) 1.59 (0.82–3.08) 0.17 — —
Urea.7 mmol/L 107/370 (28.9) 27/60 (45.0) 2.01 (1.15–3.51) 0.01 — —
Creatinine. 120 mmol/L 56/369 (15.2) 15/59 (25.4) 1.91 (0.99–3.65) 0.05 —x —
Glucose>14 mmol/L 0/330 (0) 0/53 (0) — — —k —
Definition of abbreviations: aOR=adjusted odds ratio; BP=blood pressure; BMI = body mass index; CI = confidence interval; MUAC=mid-upper arm
circumference; OR=odds ratio; Resp. = respiratory.
For age (in bold), data are shown as median and interquartile range. Otherwise, data are shown as n/N (%) with variation in denominator compared with
column header reflecting missing data. Univariable and multivariable analyses by logistic regression. For age, OR indicates change in risk of mortality with
each year increase. Twenty patients of overall study cohort of 459 excluded because of unknown 30-day outcome. The final multivariable analysis is based
on 380 patients with complete results for all included parameters.
*Excluded from multivariable analysis because of prevalence <5%.
†Excluded a priori from multivariable analysis because of assumed collinearity with systolic blood pressure.
‡Excluded a priori because of assumed collinearity with MUAC.
xExcluded a priori because of assumed collinearity with urea.
kExcluded from multivariable analysis because data were missing for .5% of patients.
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of a radiographic parameter (i.e., multilobar
involvement) (34) limits its use as a triage
tool in settings where chest radiography
might not be readily available.
Recent CAP studies corroborate our
observation that S. pneumoniae remains the
commonest identiﬁed cause of adult CAP
in sub-Saharan Africa (6, 10, 27). Universal
infant vaccination with pneumococcal
conjugate vaccination was introduced in
Malawi in 2011, approximately 2.5 years
before the start of recruitment. Following
the introduction of pneumococcal
conjugate vaccination in the United
States and South Africa, rates of adult
pneumococcal disease (including
pneumonia hospitalizations) fell rapidly as
a result of indirect protection caused by
reduced pneumococcal transmission from
vaccine recipients (45, 46). Further studies
are needed to describe the serotype
distribution of pneumococcal pneumonia
in Malawi, to determine whether targeted
vaccination programs of at-risk groups may
be beneﬁcial to tackle the persistent burden
of adult disease. Recently developed urinary
assays that can detect serotype-speciﬁc
antigens in noninvasive pneumococcal
pneumonia may provide a more
comprehensive description (47).
When adequate diagnostic tests are
performed, TB is identiﬁed in a substantial
proportion of patients presenting with
acute CAP in sub-Saharan Africa with the
major burden of disease and associated
mortality occurring in HIV-infected
individuals (7–9; 27). At 23% of those
tested and 16% of the overall cohort, the
frequency of TB is similar to that
previously reported (7–9; 27), but probably
underestimates the true burden given the
reliance on spontaneously expectorated
sputum specimens and a single specimen
submitted for culture. In most sub-Saharan
African settings, laboratory diagnosis of TB
has until recently relied on sputum smear
microscopy that has poor sensitivity,
particularly for HIV-associated TB. The
World Health Organization has advocated
an empirical “step-up” approach, whereby
antituberculous treatment is initiated for
HIV-infected adults with features of severe
respiratory infection and negative sputum
smears who fail to improve after 3–5 days
of antibacterial treatment (48). Although
this approach may limit inappropriate
antituberculous treatment, it may miss up
to 20% of patients with culture-positive
TB and risks delaying treatment in a
group of patients with a very high risk of
early death (49). The increasingly available
Xpert MTB/RIF assay used in this study
offers much improved sensitivity and is
now recommended as the ﬁrst-line
diagnostic for HIV-associated TB (50).
Rapid urine-based diagnostics (e.g.,
urine Xpert MTB/RIF, mycobacterial
glycopeptide lipoarabinomannan assay)
may have a complementary role to guide
initiation of antituberculous treatment,
particularly for acutely ill patients from
whom sputum is frequently unobtainable
(51, 52).
In keeping with recent CAP studies
from well-resourced settings that have used
molecular diagnostics (4, 53), we identiﬁed
high rates of coinfection with multiple
organisms, most commonly bacterial–
viral coisolation. Deﬁning the clinical
signiﬁcance of each organism detected
is challenging, particularly among
immunocompromised individuals.
Although coisolation may reﬂect genuine
copathogenicity or simply detection of
bystander colonizing organisms, more
complex relationships in which one
organism facilitates the acquisition or
pathogenesis of another (e.g., inﬂuenza
and S. pneumoniae) (54) are possible.
Bacterial–viral coinfection has been
associated with altered levels of innate
immune factors (e.g., CRP and IP10) (55)
and a more severe clinical course (56).
Further work is needed to deﬁne the
implications for CAP therapy and
prevention.
Radiographic facilities are limited in
most healthcare facilities in sub-Saharan
Africa where the majority of CAP patients
are initially managed. Although the clinical
case deﬁnition used in this study may have
missed some patients with radiographic
pneumonia who lacked focal signs at the
time of recruitment it nonetheless reﬂects
routine clinical practice and usefully
provides data to show how the etiologic
spectrum of disease varies with chest
radiograph ﬁndings (57). The association
of radiographic changes compatible
with infection with S. pneumoniae is
unsurprising. Although still relatively
uncommon, the greater prevalence of
invasive Salmonella infection among those
lacking radiographic pneumonia has
important implications for antimicrobial
management. Although speciﬁc radiologic
features were statistically associated
with certain pathogens, the marked
interobserver variability in interpretation of
these features suggests that the clinical
utility of this approach is limited.
In recruiting patients exclusively from a
single referral hospital, this study shares the
limitations common to many CAP
observational cohorts. Most patients were
seen at another facility before attendance;
how they were selected for referral and,
correspondingly, the characteristics and
outcome of those treated at home is
unknown. Hence, the applicability of the
ﬁndings to community-level settings is
potentially limited. Extrapolation of these
ﬁndings to other countries in sub-Saharan
Africa must also be done cautiously because
of the potential impact that variations
in such factors as TB incidence, HIV
prevalence, and climate may have on
CAP epidemiology and etiology. Given
limitations of the healthcare infrastructure
in Malawi, chronic comorbid illnesses may
be underdiagnosed. Inconsistencies in drug
supply, equipment provision, and staff
experience may result in variations in CAP
treatment that may impact patient outcome
but are not fully accounted for in analyses.
The description of CAP etiology was
limited by the lack of sputum microscopy
and culture, which may have increased
the detection of bacterial pathogens, such as
Haemophilus inﬂuenzae as has been
described in previous studies from the
region (27, 58). Similarly, we were unable
to support invasive respiratory sampling
for diagnostic testing for Pneumocystis
jirovecii and other HIV-associated
opportunistic pathogens. The low rate of
bacteremia observed may relate to both
prehospital antibiotic use and antibiotic
initiation before blood couture collection
in hospital, which occurred in up to one-
third of patients. Interpretation of the
signiﬁcance of respiratory pathogen
multiplex PCR results, particularly
for respiratory viruses, is hampered by
the lack of data from an appropriate
control population. The relative
contribution of pathogens with
seasonal transmission patterns (e.g.,
inﬂuenza) may also have been skewed
by a recruitment period that spanned 2
incomplete years.
In conclusion, more than a decade
after the introduction of ART, the major
burden of CAP in Malawi remains in
young patients with HIV rather than
the elderly patients with chronic
noncommunicable comorbidities that
ORIGINAL ARTICLE
Aston, Ho, Jary, et al.: CAP in Malawian Adults 367
predominate in well-resourced settings.
Accordingly, context-speciﬁc approaches to
severity assessment and deﬁning empirical
antimicrobial treatment are needed. The
predominance of S. pneumoniae and
inﬂuenza suggests signiﬁcant opportunities
for CAP prevention through targeted
vaccination programs. Strategies to
encourage prompt patient presentation, to
increase early detection and treatment of
TB, and to improve supportive care, in
particular the correction of hypoxemia,
should be evaluated in clinical trials to
address the high burden of CAP-related
mortality. n
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